IRCT20211214053411N1招募中未知
Comparison of the efficacy and safety of adjunctive therapy using Ketamine with Bupronorphine for patients with major depressive disorder and contaminant opium abuse: A randomized double blind, placebo- controlled clinical trial
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •Patients admitted to Ebn Sina Hospital in Shiraz with a diagnosis of major depression or depression induced by opioid use
- •Age between 18 and 60 years
- •Opium user according to DSM5 criteria
排除标准
- •Having a major comorbid psychiatric illness such as psychosis or bipolar spectrum
- •Having major physical illnesses such as cardiovascular disease - Uncontrolled blood pressure - Uncontrolled diabetes - Uncontrolled thyroid disease
研究者
相似试验
尚未招募
4 期
Effect of 10Hz rTMS as an adjunctive to pregabalin in addition to Pregabalin in Central Post Stroke Pain : A randomised double blind placebo controlled trialCTRI/2024/07/071057Professor Jayantee Kalita
招募中
不适用
The evaluation of the effectiveness of transcranial direct current stimulation (tDCS) in the management of super-refractory convulsive status epilepticusIRCT20200517047483N2Shiraz University of Medical Sciences20
尚未招募
不适用
A study to compare additional treatment with Subconjunctival and Topical Bevacizumab (a drug known to reduce recurrence in various studies) combined with Pterygium surgery versus Pterygium surgery alone on recurrence of pterygium : A multi centric trialCTRI/2018/07/014812Office of DGAFMS Ministry of Defence
已完成
4 期
Comparision of various drugs used inknee osteoarthritisCTRI/2016/02/006587Institute of Medical Sciences Banaras Hindu University Varanasi Uttar Pradesh India217
进行中（未招募）
不适用
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments.EUCTR2011-001493-25-ATovo Nordisk A/S420